Peptide guide

Semax: what it is and what the research actually shows

A synthetic ACTH fragment peptide developed and sold as a prescription nasal drug in Russia for stroke and other brain conditions. It has never been approved by the FDA, and almost all of its clinical evidence sits in Russian language journals that cannot be independently checked in full.

Byline: Mark Sommers, editor. Sources checked 08-26-2026. Every claim below links to its PubMed record or FDA page.

Quick facts

What is in it
  • One synthetic peptide, a seven amino acid fragment built from a small piece of adrenocorticotropic hormone (ACTH) with three extra amino acids attached to the end.

One molecule, not a blend. Anything sold as semax mixed with another peptide is not what was tested in any study below.

Studied for
The human studies here measured recovery after stroke using neurological rating scales plus EEG and evoked potential brain monitoring, blood levels of BDNF (a nerve growth protein tied to brain repair), disease progression and stroke risk in people with chronic reduced brain blood flow, results on eye tests including visual acuity, visual field size and optic nerve conduction in optic nerve disease, and a quality of life score in motor neuron disease. The animal and lab studies measured brain BDNF and related gene activity, a learned avoidance behavior used as a memory proxy, and gene expression patterns in brain tissue after a stroke like injury.
Human evidence, part by part
SemaxLimited9 human studies found
Approved by the FDA?
Not approved as a drug in the United States. Semax is an approved prescription drug in Russia, where it has been sold since the 1990s, but that approval does not carry over to US regulators. In July 2026 an FDA advisory committee voted to recommend semax for a list of substances that may be eligible for pharmacy compounding, which is a different and much lower bar than drug approval, and the FDA had not acted on that recommendation as of this check. See where it stands.

Benefits

  • Evidence Was linked to faster stroke recovery, especially for motor deficits, in a 110-patient comparative trial. PMID 11517472
  • Evidence Blood BDNF, a nerve-repair protein, rose after treatment and tracked with faster stroke recovery in 110 people. PMID 29798983
  • Evidence Was linked to better visual acuity, wider visual field and nerve conduction in optic nerve disease. PMID 10741256
  • Evidence Raised BDNF in the hippocampus and increased a learned memory-proxy behavior in rats. PMID 16996037
  • Suggested Discussed as a cognitive-enhancement nootropic in the West, beyond the stroke and eye conditions actually studied.
  • Suggested Promoted online for everyday focus, though Russian trials targeted stroke and optic nerve disease instead.
  • Suggested Discussed by online clinician commentary as a reasonably safe nootropic with mixed user anecdotes.

Evidence items link to the study behind them. Suggested items are claims in circulation, not results.

Reported side effects

  • No semax study publishes a numeric adverse-event table; tolerability claims are only general statements.
  • Described as generally well tolerated with a minor rate of side effects, without giving numbers. PMID 15792140
  • In a motor neuron disease trial, no problem was reported serious enough to stop treatment. PMID 18379501
  • Did not change the physical course of motor neuron disease despite a reported quality-of-life gain. PMID 18379501

Safety, before anything else

Semax is not approved as a drug in the United States. It is a prescription drug in Russia, sold there since the 1990s, and in July 2026 a US FDA advisory committee voted to recommend it for a list of substances that might become eligible for pharmacy compounding, a recommendation the FDA has not yet acted on. Most of what is known about how it works in people comes from a small number of decades old Russian studies that cannot be independently checked beyond their English abstracts. Here is every safety note in the available record, before you read anything about what it might do.

Semax

  • The acute stroke report states semax was given as part of combined intensive therapy but the available abstract includes no numeric side effect table, so no adverse event rate can be checked beyond that statement. PMID 11517472
  • Describes semax as featuring a minor percentage of side effects and being well tolerated by patients, including older age groups, but the abstract gives no numbers, rates or list of what those side effects actually were. PMID 15792140
  • In the motor neuron disease trial, the abstract reports no problem serious enough to stop or change treatment over the study period, and describes an improved emotional and motivation score, but again gives no adverse event count or table. PMID 18379501
  • No study of semax in this file publishes a numeric adverse event table of the kind modern trial registries require. Across the human studies found in a PubMed search, none has a results record posted to a public trial registry, so there is nothing outside each paper's own abstract to check any safety statement against.

We do not publish amounts or schedules of our own, on any page. The clinician commentary lower on this page quotes amounts that named clinicians state on camera, labeled and linked to the source video. Those are their words, not our guidance. Why we draw that line.

How to read the grades

Each study gets a tag. Cells in a dish means it never touched a living animal. Animals means mice or rats, usually. Small human study means a handful of people with no comparison group. Human trial means people were randomly split into treated and untreated groups, which is the only kind that can show an effect is real. Review and Systematic review sum up other studies. The full rule is on How we check.

Semax

Semax is a synthetic seven amino acid peptide built from a fragment of adrenocorticotropic hormone (ACTH positions 4 to 7) with three extra amino acids, proline, glycine, proline, attached to the end. The design intent was to keep the nervous system activity associated with that ACTH fragment while removing the hormonal activity that stimulates the adrenal glands. It was developed in Russia starting in the 1980s by the Institute of Molecular Genetics of the Russian Academy of Sciences together with the Research Institute of Normal Physiology, and has been sold there since the 1990s as a prescription nasal drug for conditions including ischemic stroke, chronic reduced blood flow to the brain, and some optic nerve disorders. In rat studies it raises levels of brain derived neurotrophic factor, a protein tied to nerve cell survival and the forming of new connections, and it shifts which genes turn on and off in brain tissue after a stroke like injury. It is not approved by the FDA and is not a component of any drug approved in the United States.

Human evidence: Limited. 9 human studies found in our search.

What has been studied

Who or what was studiedWhat was found, and the catchSource
Small human study
n = 110 people
In patients treated within the first days after a hemispheric ischemic stroke, adding semax to standard intensive care was linked to faster recovery of neurological function on rating scales, more so for motor deficits, compared with a separate group of patients who received standard treatment alone. EEG mapping and evoked potential testing were used alongside the clinical scores to track brain function.
Limit: This is one of the two studies most often cited as the foundation for semax's stroke use, and it is nearly three decades old. The comparison group was not randomized, it was a separate group of patients matched afterward for stroke severity and location, so unmeasured differences between the groups could explain part of the result. The full paper is in Russian in a journal with no English full text available online, so only the abstract can be checked, not the statistical methods behind the improvement claim.
Gusev 1997
PMID 11517472
Small human study
n = 187 people
In a group of patients at different stages of chronic cerebrovascular insufficiency, tracked with neurological exams, ultrasound of the neck vessels, brain imaging and eye exams, semax treatment was linked to clinical improvement, a slower disease course and fewer strokes or transient ischemic attacks over the study period, with side effects described as minor and the drug described as well tolerated even in older patients.
Limit: No control or comparison group is described in the available abstract, so there is no way to tell from what is public whether patients would have looked similar without treatment. The full text sits in a Russian neurology journal with no accessible English translation, so the numbers behind terms like significant improvement and reduced risk cannot be checked.
Gusev 2005
PMID 15792140
Small human study
n = 110 people
In adults recovering from ischemic stroke, blood BDNF levels rose after semax treatment regardless of when rehabilitation started, and higher BDNF levels tracked with faster and better recovery on a disability scale. Patients who did not receive semax needed to start rehabilitation early to reach a similar rise in BDNF.
Limit: Patients were sorted into semax and no semax groups by whether they happened to receive the drug, not by random assignment, so people who got semax may have differed from those who did not in ways the study cannot rule out. Blood BDNF level is a proxy measurement, not a symptom or a functional outcome by itself. This is one of the few semax papers with a full English abstract on PubMed, which is not true of most of the others in this file.
Gusev 2018
PMID 29798983
Small human study
In glaucoma patients whose eye pressure had already been brought under control, adding semax to standard neuroprotective care was linked to better results on electrophysiological and computer based tests of the optic nerve than standard treatment alone.
Limit: No patient count is given in the available abstract, and the summary reports a general advantage rather than specific numbers. The full study sits in a Russian ophthalmology journal with no accessible English translation, so how patients were assigned to groups and the figures behind the claimed advantage cannot be checked.
Kurysheva 2001
PMID 11569188
Small human study
In patients with vascular, toxic allergic or inflammatory disease of the optic nerve, two ways of delivering semax to the eye region were compared against a standard treatment only control group. The semax groups showed better visual acuity, a wider visual field, and improved color vision and nerve conduction measurements than the control group.
Limit: No total patient count or group sizes are given in the available abstract, and there is no statement that group assignment was random. The full text is a Russian ophthalmology journal article with no accessible English translation, so the figures behind the reported improvement cannot be independently checked.
Polunin 2000
PMID 10741256
Small human study
n = 27 people
In an open label trial in patients with motor neuron disease, semax did not change the course of nerve and muscle degeneration as measured by repeated needle EMG, but patients reported a better overall quality of life score, driven mainly by improved emotional state and motivation.
Limit: This was an open label trial with no placebo or control group, so both patients and raters knew who was being treated, which can inflate a subjective quality of life result. Twenty seven people is a small group for a slow, variable disease. This is also the one study in this file where semax was tested against its intended physical outcome and did not change it.
Serdiuk 2007
PMID 18379501
Animals
In rats, semax given by nasal application raised BDNF protein, a growth factor tied to learning and memory, specifically in the basal forebrain within a few hours, and the researchers identified a specific binding site for the peptide in that brain region.
Limit: This is rat brain tissue, not a human brain, and it measures a biological marker rather than behavior or memory performance in the same experiment. The work comes from the peptide's own development group in Moscow, not an outside lab.
Dolotov 2006
PMID 16635254
Animals
In rats, a single application of semax raised BDNF and its receptor trkB in the hippocampus, a brain region tied to memory, and the treated animals also showed more of a specific learned avoidance behavior used in the lab as a memory proxy.
Limit: Same origin lab as the basal forebrain paper above, again in rat brain tissue. The learned avoidance task is a narrow laboratory measure and does not directly show what happens to memory in daily human life.
Dolotov 2006
PMID 16996037
Animals
Using RNA sequencing in rats after a stroke like injury, researchers found semax shifted brain gene activity toward genes involved in nerve signaling and away from genes tied to inflammation, roughly the opposite pattern seen in untreated injury, across several hundred genes with a meaningfully changed activity level.
Limit: This is a gene activity pattern in rat brain tissue, not a measurement of recovery, symptoms or survival. It is again the same Moscow research group that developed the drug, running the same stroke model it has published on for over a decade.
Filippenkov 2020
PMID 32580520
Review
A 2026 narrative review of therapeutic peptides in aging medicine grouped semax with several unapproved research peptides, describing it as having preclinical and limited clinical evidence for neuroprotection but lacking long term safety data and systematic validation, unlike the FDA approved agents covered in the same review.
Limit: This is a narrative review, not a systematic review with a published search protocol, and it says so of itself. It drew on 20 total sources across nine different peptides, so semax gets a small slice of that, and its own conclusion is that semax lacks the clinical rigor the review says other agents in its comparison group have.
Mavrych 2026
PMID 42021992

Safety signals in the studies

  • The acute stroke report states semax was given as part of combined intensive therapy but the available abstract includes no numeric side effect table, so no adverse event rate can be checked beyond that statement. PMID 11517472
  • Describes semax as featuring a minor percentage of side effects and being well tolerated by patients, including older age groups, but the abstract gives no numbers, rates or list of what those side effects actually were. PMID 15792140
  • In the motor neuron disease trial, the abstract reports no problem serious enough to stop or change treatment over the study period, and describes an improved emotional and motivation score, but again gives no adverse event count or table. PMID 18379501
  • No study of semax in this file publishes a numeric adverse event table of the kind modern trial registries require. Across the human studies found in a PubMed search, none has a results record posted to a public trial registry, so there is nothing outside each paper's own abstract to check any safety statement against.

Most cited author in this list: Gusev, 3 of 10 sources. When a small number of groups produce most of the evidence, independent replication is thinner than the source count suggests.

Where it stands with regulators

  • Drugs@FDA query run 08-26-2026 returned NOT_FOUND. No approved product and no filed application on record. Checked 08-26-2026. Source
  • FDA 503A bulk drug substances overview page, content current as of 05/14/2026, checked 08-26-2026. Explains the three category interim compounding policy but does not itself list which substances sit in which category, and it predates the committee vote below. Source
  • FDA's own meeting page for the July 23 to 24, 2026 Pharmacy Compounding Advisory Committee session, checked 08-26-2026. Confirms semax was on the agenda for July 24 as a nominated bulk substance for cerebral ischemia, migraine and trigeminal neuralgia. Source
  • Regulatory Affairs Professionals Society report dated July 24, 2026, checked 08-26-2026. The committee voted 8 to 5 with one abstention to recommend semax for the 503A list; a related peptide reviewed the same day was voted down. Source
  • Law firm client alert, checked 08-26-2026. States that advisory committee recommendations do not authorize compounding on their own and that FDA is not required to follow them, and that formal rulemaking with public comment is still required before any listing change takes effect. Source
  • ClinicalTrials.gov API query run 08-26-2026 returned zero registered studies for semax anywhere in the world. Source

What is missing

Every human study on semax comes from Russian research groups, several from the same institute that developed the drug, and none has been independently repeated outside Russia. No study here is confirmed to have used random group assignment, most give no total patient count in what is publicly readable, and the full text of nearly every one sits behind a Russian language journal with no accessible English translation, so only a short abstract can be checked against each paper's own claims. No trial involving semax is registered on ClinicalTrials.gov. No study in this file publishes a numeric adverse event table. In the one trial that tested semax against an objective physical outcome in a degenerative disease, motor neuron disease, it did not change that outcome. FDA has never reviewed semax as a drug, and the July 2026 advisory committee vote to recommend it for a compounding list is not the same as approval and has not yet been acted on.

Clinician commentary (YouTube)

This is commentary, not evidence. 4 clinicians with large audiences discuss this on camera. Each video below is summarized in our words and linked so you can watch the source yourself. Any amounts mentioned are what the named clinician says on camera, not PeptideGauge guidance. The graded studies above remain the record of what is known. How this layer works.

Dr. Alex Tatem

In “Truth About Popular Peptides Tier List (What Works, What’s Overhyped) | Pt. 3”, Dr. Alex Tatem discusses Semax. What he says, in short:

  • He introduces it, transcribed here as CAX, as a seven amino acid heptapeptide studied for cognition and neuroprotection, especially in stroke patients.
  • He says the supporting research comes mostly from Russian researchers and calls the data a little noisy, while adding that noisy data doesn't mean the compound doesn't work, and separately notes it is exceedingly safe.
  • He reports that among people using it purely as a cognitive booster, the anecdotal hit rate is about 50/50, which he says is better than a lot of other compounds.
  • He says he personally finds it appealing for a distinct, controlled cognitive boost during long work sessions, partly because it is an amino acid sequence the body already knows how to handle.
  • He gives it a B tier ranking, placing it above the so-so C tier compounds on his list.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.

In “Every Popular Peptide Ranked | GLP-1, Growth Hormone, HCG, NAD+, IGF-1, Peptide Tier List”, Dr. Alex Tatem discusses Semax. What he says, in short:

  • He describes Semax as a seven amino acid peptide studied, mostly by Russian researchers, for cognition and neuroprotection including in stroke patients, calling the underlying data a little noisy but generally showing a safe profile.
  • He says among people using it purely as a nootropic, reports run about 50/50 positive, which he considers better than a lot of other compounds.
  • He gives Semax a B tier ranking, above what he calls the so-so C tier compounds.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.

Dr. Ashley Froese

In “11 Peptides Just Got Greenlit by the FDA (Here's What Changed)”, Dr. Ashley Froese discusses Semax. What she says, in short:

  • She lists semax among the peptides the FDA's Pharmacy Compounding Advisory Committee will evaluate at its end of July 2026 hearing, specifically for cerebral ischemia or stroke, migraines, and trigeminal neuralgia.
  • She stresses that semax being pulled off the do not compound category 2 list on April 15, 2026 does not mean it is legal to compound yet, more rulemaking and a public comment period still lie ahead, likely months away.
  • She says she has covered the science behind semax in depth in another video and points viewers there or to her course for more detail.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

In “The FDA vs. Peptides: The Truths About DSIP, Semax, & Epitalon”, Dr. Ashley Froese discusses Semax. What she says, in short:

  • She says Semax has a large cult following in the cognitive enhancement space, has human study data behind it, and is approved for use in Russia and parts of Eastern Europe.
  • She says the FDA committee is evaluating it for cerebral ischemia or stroke recovery, migraines, and trigeminal neuralgia, and notes it was originally developed as a high-potency countermeasure for acute brain trauma, strokes, and severe cognitive disorders for the Soviet military and space program.
  • She says most peptide enthusiasts today use Semax for brain fog and focus, and says that use case makes sense given how it's thought to work.
  • She explains Semax as a synthetic ACTH fragment that spikes brain-derived neurotrophic factor (BDNF) through selective brain ACTH receptors, comparing BDNF to miracle grow for brain cells.
  • She says the FDA's concern is that too much BDNF can raise glutamate and lead to a heightened pain response or seizures, but notes Semax's short 1 to 2 hour half-life and the brain's natural feedback loops make that kind of runaway effect unlikely.
  • She says the US largely dismisses the existing human data on Semax because it comes out of Eastern Europe and doesn't meet Western clinical trial standards.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

2 more videos where Dr. Ashley Froese covers Semax

In “Dr. Reveals What Really Happened at the FDA Meeting on Peptides”, Dr. Ashley Froese discusses Semax. What she says, in short:

  • She says that by the end of the two-day meeting, the committee voted yes on six of the seven peptides discussed, including semax.
  • She says DSIP was the only one of the seven voted no.
  • She doesn't go into semax's mechanism or uses in this video, only naming it among the six peptides the committee recommended.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

In “Learn Peptides So Fast it's UNREAL”, Dr. Ashley Froese discusses Semax. What she says, in short:

  • She places semax in her focus and cognitive enhancement bucket, noting it was developed in Russia and studied extensively for cognitive effects.
  • She says its main mechanism is increasing brain derived neurotrophic factor, which she calls fertilizer for your neurons.
  • She says it has been shown to improve mental focus, clarity, and alertness, and is small enough to be absorbed through the nasal mucosa, which is why people use nasal sprays.
  • She also places semax in her anxiety and stress bucket, saying it can bring cortisol back to baseline after very stressful events.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

Dr. Craig Koniver

Dr. Craig Koniver does not run a channel of his own. Each video below is an interview published by the show that recorded it.

In “Dr. Craig Koniver - The Godfather of Peptides | SRS #330” on Shawn Ryan Show, Dr. Craig Koniver discusses Semax. What he says, in short:

  • He puts semax in the nervous system category of peptides and says it was developed in Russia many decades ago.
  • He says it was developed to help people who have had a stroke or a traumatic brain injury.
  • He calls selank its cousin and says the combination of the two is like a natural Adderall.
  • He says his clinic makes that combination into a nasal spray, which he likes because it is a quick hit to the nervous system and patients can redose it.
  • He hedges that he is not going to say it is perfect and that it is certainly not for everybody.

One called CAX, which was developed in Russia many decades ago to help people who've had a stroke, people who had a traumatic brain injury.

the combination of CAX and Sank is like a natural aderall

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Is Peptide Therapy the Future of Medicine? | Dr. Craig Koniver” on The Ancient Health Podcast, Dr. Craig Koniver discusses Semax. What he says, in short:

  • He says he really likes semax and calls it one of the Russian peptides, still pretty widely used in Russia.
  • He says it is used there for people after a stroke, a traumatic brain injury or a concussion.
  • He says semax seems to increase BDNF levels, which he describes as the juice the nervous system or the neurons live in.
  • He says it works really well combined with selank, its chemical cousin.
  • He prefers it as a nasal spray for cognitive use because it hits the nervous system quickly, while noting the tradeoff that a nasal spray will not stay in the system very long.
  • He says that because it is so safe you could run an injection in the background and use a nasal spray of semax or selank on top of it.

cmax seems to increase bdnf levels bdnf brain deride neurotropic factors kind of the juice the nervous system or the neurons live in

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

1 more video where Dr. Craig Koniver covers Semax

In “Episode 95: Dr. Craig Koniver - Founder of Koniver Wellness, Performance Medicine Expert” on Habits & Hustle w/ Jennifer Cohen, Dr. Craig Koniver discusses Semax. What he says, in short:

  • He raises semax when asked whether peptides can help with anxiety or replace antidepressants.
  • He says it was developed in Russia and given to people after a stroke or traumatic brain injury.
  • He says what it does is increase BDNF levels in the brain, which he describes as the juice the neurons live in.
  • He calls it a very powerful one for people after an injury, for people feeling depressed, and for people who cannot focus.
  • He says it is a great option for someone who wants a substitute for something like Adderall.
  • He says he then combines it with selank, its chemical cousin.

what that does is it increases what's called the bdnf levels in the brain which is like the juice that the neurons live in

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

Dr. Jones, DC

In “Doctor Explains the Semax & Selank Cognitive Peptide (Risks, Benefits & Who It’s For)”, Dr. Jones, DC discusses Semax. What he says, in short:

  • He rejects the smart drug framing, saying semax is not a stimulant and does not floor the gas the way caffeine or a study drug does.
  • He says semax comes from a small fragment of a natural stress signaling molecule the body already makes, and that the research describes it as working through BDNF.
  • He describes its effect as helping the brain handle stress and recover its own signal, which he calls repair and resilience rather than stimulation.
  • He says the people he coaches who feel it describe the fog lifting, tasks no longer feeling like pushing a boulder, and more drive to start things they have been avoiding.
  • He argues it only does something when there is a real gap to close, using a glasses analogy, and says the person already sleeping, eating and training well who feels genuinely sharp will feel almost nothing.
  • He gives a specific caution that because semax leans toward drive and activation it is not right for everyone, naming high baseline anxiety, sensitivity to stimulation, a seizure history, being under 25, or being on serotonin or dopamine medications as reasons to talk to a medical team first.
  • He notes it is a nasal spray rather than an injection and works in a short fast window, which he frames as a feature because you find out quickly whether it does anything for you.
  • He says a large share of the did nothing reports are a product problem rather than a peptide problem, pointing at underdosed, degraded or mislabeled research chemical market spray.

What I see Semax leaning toward, drive, focus, clarity, the get-up-and-go.

They're not flooring the gas, they're turning the engine.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Doctor Reveals The 10 Most POWERFUL Peptide Stacks (Science Backed Peptides)”, Dr. Jones, DC discusses Semax. What he says, in short:

  • He pairs semax with selank as a cognitive optimization stack and says the two Russian peptides are used together in many cases because they create a balance.
  • He assigns semax the role of laser focus and mental performance within that pairing.
  • He says research suggests semax may increase brain derived neurotrophic factor, which he compares to fertilizer for the brain.
  • He reports that patients prescribed it commonly describe improvements in learning, memory and cognitive processing, and says that aligns with what he would expect if BDNF rises.
  • He notes in the same breath that deep and long fasting can also raise BDNF, framing the peptide as an enhancement to something achievable another way.
  • He states the format and dosing his doctors use as nasal spray at around 1 milligram per application up to three times a day, alternating nostrils, with a break after two to three months of daily use.

Doing can be anywhere around 1 milligram per application up to three times per day.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

Common questions

Is semax approved by the FDA?

No. A search of the FDA's own drug database found no approved semax product and no application on file. It is an approved prescription drug in Russia, which is a separate system with different evidence requirements, and that Russian approval does not transfer to the United States. In July 2026 an FDA advisory committee voted to recommend semax for a list of substances that pharmacies might be allowed to use in compounding, but that vote is advisory, is not binding on the agency, and is not the same thing as drug approval. FDA has not yet acted on it.

What is semax supposed to do?

It is a small peptide built from a piece of a hormone called ACTH, designed to act on the nervous system. In Russia it has mainly been studied and sold for stroke recovery, chronic reduced blood flow to the brain, and some optic nerve conditions. In animal studies it raises a brain growth factor called BDNF and changes gene activity in injured brain tissue. The human studies in this file are about stroke, blood flow and eye disease, not about general focus or cognition in healthy people, which is a common claim made for it outside these studies.

Why is most of the research on semax hard to check?

Almost every human study on semax was published in a Russian language journal, several decades ago, without an English full text available anywhere online. What can be read is the English abstract PubMed carries for each paper, which is often only a few sentences, without the actual numbers, statistical tests or full methods behind the stated results. None of these studies has a results record posted to a public trial registry the way modern trials do, so there is no independent record to check the paper's own summary against.

Has any trial on semax run in the United States or elsewhere outside Russia?

Not that shows up in a search. ClinicalTrials.gov returned zero registered studies for semax as of the date this file was checked, and every study included here was conducted by Russian research groups, several of them by the same institute that developed the drug.

Did semax work in every study that tested it?

No. In the one study here that tested semax against a slow degenerative nerve disease, motor neuron disease, it did not change the physical course of the disease as measured by repeated nerve and muscle testing. Patients did report a better quality of life score in that same study, but that came from an open label design with no placebo group, which makes a subjective score easier to move than an objective physical measure.

What do we actually know about side effects?

Very little in checkable form. Two of the human papers describe semax as generally well tolerated with a minor rate of side effects, and one reports no problem serious enough to stop treatment, but none of the available abstracts give a number, a rate, or a list of what those side effects were. No adverse event table has been found in a publicly checkable form for any semax study.

What would make this evidence base stronger?

An independently run, randomized, placebo controlled trial outside Russia and outside the labs that developed the drug would matter most. So would full English translations of the existing Russian trials, with actual patient counts, group assignment methods and statistics, plus a published numeric adverse event table from at least one trial. Right now the record is old, comes from a small number of connected research groups, and cannot be checked past what a short abstract states.

Sources

  1. Dolotov (2006). PMID 16635254
  2. Dolotov (2006). PMID 16996037
  3. Filippenkov (2020). PMID 32580520
  4. Gusev (1997). PMID 11517472
  5. Gusev (2005). PMID 15792140
  6. Gusev (2018). PMID 29798983
  7. Kurysheva (2001). PMID 11569188
  8. Mavrych (2026). PMID 42021992
  9. Polunin (2000). PMID 10741256
  10. Serdiuk (2007). PMID 18379501

Semax does not appear on FDA's list of bulk drug substances that can be used in section 503A compounding, as posted through that list's own content date of 05/14/2026. On July 24, 2026, an FDA advisory committee voted to recommend adding it, but that recommendation is not binding and FDA has not completed the rulemaking needed to act on it. Checked 08-26-2026.

Want these studies next to every other one on the site?

Open the evidence table

Mixing a vial? Do the math with the calculator.

Open the calculator